Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268179 | 0.81 | EPHX2 (0.32) | APLNREPHX2 | |
| SCHEMBL5401862 | 0.80 | FFAR3 (0.41) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL4749316 | 0.80 | FFAR3 (0.41) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL5401869 | 0.80 | FFAR3 (0.41) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL5410650 | 0.80 | FFAR3 (0.41) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL5410652 | 0.80 | FFAR3 (0.41) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL25228836 | 0.79 | TDP1 (0.34) | APLNREPHX2 | |
| SCHEMBL25253736 | 0.79 | EPHX2 (0.34) | APLNRNPSR1EPHX2 | |
| SCHEMBL4327201 | 0.78 | EPHX2 (0.33) | FFAR3APLNRCYP2C19EPHX2 | |
| SCHEMBL600836 | 0.77 | FFAR3 (0.54) | FFAR3MAPK1TP53NFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-4448492-B1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | REGLAGENE, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4448492-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | Reglagene, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4384503-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118119595-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023111996-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE HOLDING, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| WO-2023018781-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | FFAR3 2191/4885APLNR 2495/4885MAPK1 2222/4885 |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | CD47, RB1, TP53 | FFAR3 3230/4885APLNR 472/4885MAPK1 4003/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | FFAR3 3650/4885APLNR 3697/4885MAPK1 1593/4885 |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | FFAR3 3650/4885APLNR 3697/4885MAPK1 1593/4885 |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | CD47, RB1, TP53 | FFAR3 3230/4885APLNR 472/4885MAPK1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.